Next Article in Journal
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Next Article in Special Issue
Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers
Previous Article in Journal
Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring
Previous Article in Special Issue
Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
 
 
Review

Article Versions Notes

Cancers 2022, 14(5), 1171; https://doi.org/10.3390/cancers14051171
Action Date Notes Link
article xml file uploaded 24 February 2022 11:51 CET Original file -
article xml uploaded. 24 February 2022 11:51 CET Update https://www.mdpi.com/2072-6694/14/5/1171/xml
article pdf uploaded. 24 February 2022 11:51 CET Version of Record https://www.mdpi.com/2072-6694/14/5/1171/pdf
article html file updated 24 February 2022 11:52 CET Original file -
article html file updated 1 August 2022 02:30 CEST Update https://www.mdpi.com/2072-6694/14/5/1171/html
Back to TopTop